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The transient assembly of multiprotein complexes mediates many aspects of cell regulation and sig-
nalling in living organisms. Modulation of the formation of these complexes through targeting protein
eprotein interfaces can offer greater selectivity than the inhibition of protein kinases, proteases or other
post-translational regulatory enzymes using substrate, co-factor or transition state mimetics. However,
capitalising on proteineprotein interaction interfaces as drug targets has been hindered by the nature of
interfaces that tend to offer binding sites lacking the well-deﬁned large cavities of classical drug targets.
In this review we posit that interfaces formed by concerted folding and binding (disorder-to-order
transitions on binding) of one partner and other examples of interfaces where a protein partner is bound
through a continuous epitope from a surface-exposed helix, ﬂexible loop or chain extension may be more
tractable for the development of “orthosteric”, competitive chemical modulators; these interfaces tend to
offer small-volume but deep pockets and/or larger grooves that may be bound tightly by small chemical
entities. We discuss examples of such proteineprotein interaction interfaces for which successful
chemical modulators are being developed.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Multiprotein assemblies mediate the majority of cellular pro-
cesses, including receptor activation, signal transduction, DNA
replication, recombination and repair, and other regulatory events
that require high signal-to-noise in cell regulation. Multiprotein
assemblies often arise from initial weak binary interactions: þ44 1223 766002.
r Ltd. This is an open access articlefollowed by cooperative, higher-order complex formation, giving
high selectivity while at the same time being transient as required
for termination of regulatory signals (Higueruelo et al., 2013a).
Multiprotein regulatory systems are assembled mainly through
proteineprotein interactions (PPIs). Whereas enzyme superfam-
ilies that mediate many signalling events may number hundreds of
homologues in the human genome e more than 500 protein ki-
nases and over 600 putative E3 ubiquitin (Ub) ligases (Li et al.,
2008) e multiprotein regulatory systems differ widely across
each superfamily. The speciﬁcity of PPIs offers potential for the
development of chemical and biological modulators that target
speciﬁc pathways, with advantages of selectivity that tend to beunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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perfamilies, which tend to be mechanism based, targeting transi-
tion/intermediate states or co-factor-binding sites that are similar
across the superfamily (Bolanos-Garcia et al., 2012).
Using criteria derived from retrospective analyses of successful
drugs, proteineprotein interaction sites have historically been
described as undruggable (Hopkins and Groom, 2002). Indeed,
many proteineprotein interfaces, especially those in obligate
complexes such as homo-oligomers for the presence of which
usually improves stability, have been viewed as large, ﬂat and
featureless, and thus difﬁcult targets for the development of small
molecule antagonists (Blundell et al., 2000, 2006; Jones and
Thornton, 1996). With the wealth of information available from
structural biology programmes, and advances in experimental and
computational assessment of druggability, this traditional view of
proteineprotein interaction interfaces is being reassessed (Kastritis
and Bonvin, 2013; Loving et al., 2014; Villoutreix et al., 2014), pre-
senting new insights for the development of “orthosteric” PPI
modulators that compete for the binding-site surface of a PPI
interface, typically with the objective of sterically inhibiting the
association of a multiprotein complex.
In this review we highlight the importance of relatively small
pockets that can lead to very selective binding at PPI interfaces
(Blundell et al., 2006; Jubb et al., 2012; Koes and Camacho, 2012a,
2012b). We show that small, single-residue sub-pockets and re-
gions of surface depth bound by continuously interacting peptide
segments extend the concept of druggability in ways peculiar to
proteineprotein interactions (Ben-Shimon and Eisenstein, 2010;
Fuller et al., 2009; Guo et al., 2014; Koes et al., 2012; Kozakov
et al., 2011; Li et al., 2004b; London et al., 2010, 2013; Rajamani
et al., 2004; Winter et al., 2012) and provide tractable sites for
the development of chemical modulators (Arkin et al., 2014). We
posit that interactions involving short peptides, linear binding
motifs within larger intrinsically disordered regions or within loops
or loop-termini of globular proteins, and possibly linear epitopes
arising from surface exposed helices, can provide promising bind-
ing sites. The loss of entropy on binding a ﬂexible peptide is likely
countered by binding larger sidechains, such as those of trypto-
phan, tyrosine, phenylalanine or arginine, in distinct preformed
pockets (Blundell et al., 2006), or even smaller hydrophobic resi-
dues such as alanine in pockets where they may relieve energeti-
cally “unhappy” surface waters (Huggins et al., 2011).
2. Flexibility in partner interactions
Binary PPIs, which have been targeted in drug discovery and in
which different degrees of conformational change and loss of en-
tropy occur on binding, can be described by three models: those
where both partners have preformed, relatively rigid structures;
those where one or both of the preformed structures undergo
signiﬁcant conformational changes on interaction; and those
where one of the structures folds as it binds (Fig. 1) (Blundell and
Wood, 1982; Blundell et al., 2006; Pawson and Nash, 2003). There
are also some cases where both partners may fold on interaction,
but these are relatively uncommon and may less likely provide
targets, at least for binding to one of the partners in isolation; for
example where homodimers that are expressed simultaneously
fold together permanently in an intertwined or interdigitated
structure (Bonvin et al., 1994; Kishan et al., 1997). Numerous da-
tabases including the 3D Interaction Domains (3DID (Stein et al.,
2011); http://3did.irbbarcelona.org/), Domain Annotated Pro-
teineprotein Interaction Database (DAPID (Chen et al., 2006);
http://gemdock.life.nctu.edu.tw/dapid) and PICCOLO (Bickerton
et al., 2011) (http://www-cryst.bioc.cam.ac.uk/piccolo), have
documented structural aspects of PPIs and shown that each of thesemodels is quite common; for reviews of structures, lists of data-
bases and tools for studying proteineprotein interactions see
(Tuncbag et al., 2009; Villoutreix et al., 2013; Winter et al., 2012).
The ﬁrst two models involve interactions between globular
proteins (see Fig. 1). These represent the “traditional” PPI interface,
often described as large (~1500e3000 Å2), ﬂat and relatively
featureless interfacial surfaces (Blundell et al., 2000; Jones and
Thornton, 1996). The view that these interfaces are featureless
has been challenged by the discovery that a few amino acids e so-
called hotspots (Clackson and Wells, 1995) e may contribute the
majority of interaction free energy in many PPI systems, giving
reason for some optimism with respect to targeting speciﬁc “hot
regions” with chemical modulators (Bogan and Thorn, 1998;
Clackson and Wells, 1995; Cukuroglu et al., 2014; Wells and
McClendon, 2007). It has been proposed that continuously inter-
acting interface “segments” (Jones and Thornton, 1996; London
et al., 2013; Pal et al., 2007) may also play a major role in the ar-
chitecture of globular protein interfaces, for example the interfaces
in TEM1-BLIP and EphB4-EphrinB2 (London et al., 2010).
The third model of protein interaction involves a natively un-
structured protein that folds upon interactionwith another partner.
This was proposed for peptide hormones in the 1970s by Robert
Schwyzer (Schwyzer et al., 1979) and experimentally exempliﬁed
by X-ray analysis and NMR studies of glucagon in the Blundell and
Wüttrich labs (Braun et al., 1983; Sasaki et al., 1975) suggesting a
disorder-to-order transition on receptor binding from glucagon
with a single turn of helix in solution by NMR (Braun et al., 1983) to
one with a much longer region deﬁned by X-ray analysis in the
trimer (Sasaki et al., 1975) and at lipid interfaces (Braun et al., 1983)
and proposed at the receptor (Blundell, 1979; Blundell and Wood,
1982). Subsequently, Wright & Dyson (Wright and Dyson, 1999,
2009) showed that such concerted folding and binding involving
peptides or disordered regions of polypeptide chains is actually
widespread in intracellular regulatory systems. To obtain a high-
afﬁnity interaction, it would be expected that the smaller surface
area provided by peptides and small continuous epitopes requires
surface pockets to anchor the peptide in order to maximise inter-
molecular interactions and to beneﬁt entropically from surface
water release into bulk solvent.
An example of a proteineprotein interface involving concerted
folding and binding of a ﬂexible peptide is the binding of human
recombinase Rad51 to BRCA2 in an interaction that is essential for
DNA double-strand-break repair through homologous recombina-
tion (Pellegrini et al., 2002). The BRC4 peptide found in BRCA2 folds
into a deﬁned 3-dimensional structure only upon interacting with
Rad51, a disorder-to-order transition (Fig. 2) (Pellegrini et al., 2002).
BRCA2 binding disrupts self-association of RAD51 by mimicking
RAD51's conserved self-association motif, FxxA (Pellegrini et al.,
2002). The conserved phenylalanine of the FxxA motif of BRC4
binds in a deep “anchor” pocket of Rad51, while the conserved
alanine binds in a small hydrophobic pocket. Binding to both
pockets probably contributes to favourable entropic changes in the
system through the release of energetically “unhappy” waters
(Huggins et al., 2011).
3. The landscapes of pairwise proteineprotein interfaces
Drug-like molecules typically exert their actions through bind-
ing to high-afﬁnity sites of the right shape and chemical compo-
sition. These were traditionally viewed to not be present in the
relatively ﬂat and featureless PPI interfaces. Analyses of PPI in-
terfaces using new computational tools can identify key residues in
interfaces mediating the proteineprotein interaction (Pires et al.,
2014) and potential binding sites (Hendlich et al., 1997; Kalidas
and Chandra, 2008; Laurie and Jackson, 2005; Morita et al.,
Fig. 1. Three models of binary proteineprotein interactions. (a) Preformed globular structures that interact through a discontinuous epitope with no conformational change. (b)
Preformed globular structures that adopt a novel conformation in the complex. (c) Unstructured proteins that fold on binding their partners. Reproduced with permission from
Blundell T.L. et al. (2006).
Fig. 2. PPI involving RAD51 and its homologues. (a) The structure of RAD51 complexed with the region BRC4 of BRCA2 demonstrating the existence of two well-deﬁned pockets
on RAD51 that are occupied by side chains of the conserved FxxA motif. RAD51 is shown as grey van-der-Waals surface. BRC4 is shown in purple cartoon form. Residues within a 4 Å
radius of the FxxA motif are highlighted in red on the RAD51 surface. (b) Sequences of homologous repeats in human BRCA2. (c) An equivalent view of P. furiosus RadA in a protein
oligomeric ﬁlament showing the similarity of the interface with that of the RAD51 BC4 complex. The interacting oligomerisation region of the adjacent RadA protomer is shown as a
purple cartoon. (d) Oligomerisation sequences of RAD51 orthologues and RadA. Reproduced with permission from Winter A. et al. (2012).
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inhibitors do indeed exploit multiple, small volume pockets (Fuller
et al., 2009), which often play roles as “anchors” and/or hotspots in
the interface (Ben-Shimon and Eisenstein, 2010; Jubb et al., 2012; Li
et al., 2004a; Rajamani et al., 2004) and/or are potential fragment
binding sites (Jubb et al., 2012; Scott et al., 2013; Zerbe et al., 2012).
Recently we have analysed a non-redundant set of 15,500
pairwise, non-overlapping PPI interfaces curated from the Protein
Databank (PDB), from binary and higher-order complexes. We have
distinguished between interactions of proteins including enzymes
with peptides on the one hand, and homologous and heterologous
globular interaction interfaces on the other. We compared seg-
mentation (binding epitope continuity), solvent accessibility, sec-
ondary structure, interatomic interactions and binding depth (Jubb
et al., in preparation), systematically treating each protein in turn as
receptor and measuring the depth occupied by each residue using
the program Ghecom (Kawabata, 2010). Ghecom measures the
smallest probe size that cannot enter a cavity (Rinaccess), as a per-
residue measure of depth of occupation or formation of a binding
site. Our preliminary data indicate that while protein-peptide in-
teractions make better overall use of interface surface pockets on
their protein partners compared to other classes of interaction
(Fig. 3a), interactions between two globular proteins often make
use of deep interaction sites (Fig. 3b), even if only via a small pocket
ﬁtting a single residue. A remaining challenge is to identify how
best to utilise the depth used by PPI partner proteins in the
development of chemical modulators. Pocket detection software is
important for this purpose, however detection algorithms para-
meterised for the detection of “traditional”, large volume single
pockets may miss potential, albeit more challenging sites for
modulation, which are hidden in the landscape of larger pro-
teineprotein interfaces.
4. How ﬂexible loops and extensions might help
If ﬂexible peptides exploit well-deﬁned pockets, is this also true
of ﬂexible regions in globular regions when they mediate pro-
teineprotein interactions?
Preliminary analysis of the secondary structures utilised by
deeply bound residues indicate that, while solvent inaccessibleFig. 3. Residue binding modes at pairwise PPI interfaces. (a) Comparison of binding site
represents a residue contributed by the shortest chains in each interface pair. The abscissa
using Rinaccess (see text). The scale ranges from <2.5 Å, which represent deep binding pockets
environment around the residue is, measured as the deepest partner protein atom found wit
proportionally make better use of the concavity available to them, whereas for globular interf
(b) Comparison of the binding mode of the deepest bound residues from interfaces of diffe
residue contributed at pocket classiﬁcations on the ordinate, which are based on Rinaccess (see
to the interface, i.e. the same protein sequence bound with 180 rotational symmetry.residues bound deep in pockets are very often found in helices,
there are many examples of loop, bend and turn residues that are
deeply bound (Fig. 4).
One example of the involvement of loop residues at interfaces is
in camelid and nurse shark heavy chain-only (VHH) antibodies that
are approximately 10 times smaller than conventional immuno-
globulin G's, and lack light chains (Hamers-Casterman et al., 1993;
Holliger and Hudson, 2005). The elucidation of their crystal struc-
tures has revealed framework regions and complementarity-
determining regions similar to conventional immunoglobulins
(De Genst et al., 2006; Desmyter et al., 1996; Spinelli et al., 1996).
Interestingly, many VHH chains have longer complementarity-
determining region 3 (CD3) loops (Muyldermans et al., 1994),
which facilitate binding into deeper cavities not recognised by
conventional antibodies (De Genst et al., 2006; Lauwereys et al.,
1998; Stijlemans et al., 2004). For example, VHH antibodies have
even been developed as competitive enzyme inhibitors, with the
crystal structure of a VHH inhibitor of lysozyme revealing the loop
inserted deep into the active pocket (Desmyter et al., 1996). The
resulting interaction is a prime example of the loops within a
globular protein utilising deeper pockets and anchoring the part-
ners. These features may also occur in conventional antibodies in
which the CD3 loop is longer.
It is clear that similar features may also occur in other systems
where ﬂexible loops mediate proteineprotein interactions. An
obvious example is in the self-association of RAD51 through loops
containing the conserved FxxA repeats in nuclear protein ﬁlaments,
for example deﬁned by Shin et al. (Shin et al., 2003) in archaeal
Rad51 structures and mimicked in the BRC repeats of BRCA2 (see
above). We are currently analysing our structural proteineprotein
interaction databases to see how widespread this feature might be
(Fig. 4) and whether it can provide useful clues about potentially
druggable sites.
Interactions involving the termini of a protein have also been
exploited in the development of peptide PPI inhibitors, for example
the angiotensin II receptor antagonists mimicking Angiotensinogen
(Brunner et al., 1973). Further examples of the involvement of
ﬂexible extensions in PPI are found in the binding of HGF/SF to the
Met tyrosine kinase receptor (Met), which initiates a number of
downstream signalling events including cell proliferation, motility,depth utilisation by residues in different classes of pairwise PPI interface. Each point
indicates how deeply a residue is bound into the partner protein's surface, measured
, to 10.5 Å, which represents ﬂatness. The ordinate measures how deep the local pocket
hin 5 Å of the residue of interest. The 2D density mapping shows that peptide interfaces
aces the majority of interface residues lie ﬂat against binding surfaces of variable depth.
rent classes. The ordinate counts the number of interfaces with the deepest interface
text). Isologous homopairs refer to protomer pairs which contribute the same residues
Fig. 4. Pocket occupation by interface residues of different secondary structures. The secondary structure of buried (a) and solvent exposed (b) interface residues occupying
concavities varies by the type of interface. Together, loop and turn regions dominate the examples of pocket bound residues in solvent exposed environments, whereas buried
residues bound in pockets and grooves tend to be found in helices. Interface residue data are derived from a non-redundant subset of pairwise, non-overlapping PDB interfaces.
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2003). This interaction occurs both through high- and low-
afﬁnity binding sites of the N-terminal and C-terminal regions of
HGF/SF respectively to the b-propeller sema-domain of the Met
receptor (Hartmann et al., 1998; Holmes et al., 2007; Kirchhofer
et al., 2004; Lokker et al., 1992). The N-terminal NK1 region of
HGF/SF occurs as a natural splice form and has been shown able to
form a high-afﬁnity association with Met in the presence of hepa-
rin, with the crystal structure revealing a patch of amino acid res-
idues (Glu159, Ser161, Glu195 and Arg197) crucial for the
interaction and activation of Met on either side of the homodimer
(Chirgadze et al., 1999; Ultsch et al., 1998; Youles et al., 2008). These
residues form a similar cavity to the lysine-binding pockets of other
kringle domains and this has been proposed to mediate the
dimerisation and activation of the Met receptor. Indeed current
work in our laboratory shows that a highly charged segment of a
loop of MET harbouring the furin cleavage site of MET (E302-E312:
EKRKKR j STKKE) may contribute a secondary interface with the
lysine-binding pocket of kringle 125 (Blaszczyk et al., in
preparation). Intriguingly, NK1 can even be converted into a re-
ceptor antagonist of Met by mutations that alter this interface
(Tolbert et al., 2007).
Interactions with the Met sema domain by the C-terminal
serine-protease-like domain of HGF/SF are also likely to be the
result of a combination of ordereorder and disorder-order binding.
For example, this lower-afﬁnity binding site of HGF/SF contains a
number of residues linked to reduced Met signalling. This interac-
tion is similar to the substrate processing region of serine proteases,
with a core triad of homologous catalytic residues, a ‘hot-spot’, and
interactions with the corresponding c220 activation domain loop
(Stamos et al., 2004). From the crystal structure of the complex, it
was observed that these regions interact with three separate loops
of the Met sema domain (Stamos et al., 2004).
5. Chemical modulators targeting small pockets in PPIs
Several chemical methodologies designed to modulate PPI in-
terfaces, in particular interfaces with deep pockets and grooves,
including alpha-helical mimetics (Fletcher and Hamilton, 2005)
and stapled peptides, target a-helical peptide molecular recogni-
tion sites (Chang et al., 2013; Raj et al., 2013). Successful target
interfaces include Bcl-2/XL:BAD (Oltersdorf et al., 2005), BH3:Mcl-1
(Stewart et al., 2010), p53:MDM2/X (Bernal et al., 2010), and
MAML-1:Notch (Moellering et al., 2009), all of which involvehelices central to the proteineprotein interactions and are likely
concerted folding-and-binding interactions. Possibilities for b
strands to be used as mimetic templates are also being explored
(Watkins and Arora, 2014).
An analysis of different PPI revealed that for many targets it
would be necessary to expand the available chemical diversity
space in order to identify small-molecule PPI inhibitors (Pagliaro
et al., 2004). One of the most promising strategies for the identi-
ﬁcation of small-molecule PPI inhibitors has been fragment-based
drug discovery, which is an effective tool to rapidly explore a
much larger chemical space. Fragment-based drug discovery in-
volves exploration of chemical space using molecules with mo-
lecular weights <300, resulting in initial hits that bind with low
afﬁnity. As a consequence they usually do not disrupt proteine-
protein interfaces, unless they are tethered (Wells and McClendon,
2007). An alternative fragment-based approach is to stabilise the
uncomplexed components of the multiprotein system in solution
and employ biophysical methods e nuclear magnetic resonance
(NMR), X-ray crystallography, surface plasmon resonance (SPR),
differential scanning ﬂuorimetry (DSF) or isothermal calorimetry
(ITC) to detect fragment binding (Blundell et al., 2002; Hajduk and
Greer, 2007; Murray and Blundell, 2010; Shuker et al., 1996). Sta-
bilisation for crystallography by antibodies of otherwise rarely
sampled monomer conformations has been demonstrated as an
exciting tool to explore protein conformational space for drug
discovery, particularly with respect to making allosteric effecting
sites available to small-molecule fragment binding in crystals
(Lawson, 2012). Fragment hits derived from these approaches can
subsequently be evolved into larger lead-like and drug-like mole-
cules with higher afﬁnity and potency.
One example of a successful fragment-driven campaign against
a PPI interface is the RAD51:BRCA2 interaction (introduced above).
Hyv€onen and coworkers have engineered a monomeric form of
RAD51 by humanising a thermostable archaeal orthologue, RadA,
for use in fragment screening (Scott et al., 2013). The initial frag-
ment hits were carefully validated biophysically by ITC and NMR
techniques and observed by X-ray crystallography to bind in a
shallow surface pocket that is occupied in the native complex by
the side chain of a phenylalanine from the conserved FxxA inter-
action motif found in BRCA2 (Scott et al., 2013). This represents the
ﬁrst report of fragments or any small molecule binding at this
proteine protein interaction site, and shows that small molecules
targeting hotspots can effectively target interactions involving
concerted folding and binding.
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second generation, less costly alternatives to the use of antibodies
to directly compete for the binding sites. One application might be
to use small-molecule inhibitors to target the binding sites
described above of the Met interactions with HGF/SF, so providing
less expensive agents than the antibodies designed to target the
HGF/SF (Cao et al., 2001) and the Met sema domain (Petrelli et al.,
2006).
As experimental data on ﬁrst-generation PPI inhibitors are
becoming increasingly available, several databases now record in-
formation on small-molecule inhibitors of proteineprotein in-
teractions. TIMBAL (Higueruelo et al., 2013b, 2009) integrates
chemical assay information from ChEMBL (Bento et al., 2014;
Gaulton et al., 2012) whereas 2P2Idb (Basse et al., 2013; Bourgeas
et al., 2010) records proteineprotein interfaces where the struc-
tures of both proteineprotein complex and protein-inhibitor
complex have been deﬁned. Analysis of these databases opens av-
enues to improvement of PPI inhibitor design. For example, analysis
of the TIMBAL database revealed that current orthosteric PPI in-
hibitors tend to be relatively large and have low lipophilic efﬁ-
ciency, indicating potential unsuitability for use as oral drugs
(Higueruelo et al., 2012). In the pursuit of ADMET favourable in-
hibitors, at one of the extremities of the small molecules chemists
have engineered clusters of hydrophilic regions (Kuenemann et al.,
2014). Machine-learning approaches have also helped identify
chemical rules to help guide design of chemical libraries for PPI
screening, with the molecular shape being an important determi-
nant and the ‘Rule of 4’ providing a rapid method to enrich a library
for PPI inhibitors (Hamon et al., 2014; Neugebauer et al., 2007;
Reynes et al., 2010). We hope that the new insights described in
this review coupled with analysis of current and future PPI in-
terfaces and their chemical modulators will result in more effective
PPI modulators with improved molecular properties, opening the
doors to more speciﬁc, targeted, safe and effective therapeutics.
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